@article{7abd9a47cf1743618262815e4b36ba72,
title = "A Response to: Letter to the Editor with Regard to the Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: A Health Economic Analysis in Sweden",
keywords = "Advanced hybrid closed-loop, Cost-effectiveness, Sweden, Type 1 diabetes",
author = "J. Jendle and Buompensiere, {M. I.} and Holm, {A. L.} and {de Portu}, S. and Malkin, {S. J.P.} and O. Cohen",
note = "Funding Information: Johan Jendle has received speaker{\textquoteright}s and/or consultant fees from Abbott, Ascensia, AstraZeneca, Boehringer Ingelheim, Eli-Lilly, Medtronic, Nordic Infucare, Novo Nordisk and Sanofi. Maria Ida Buompensiere, Simona de Portu and Ohad Cohen are employees of Medtronic International Trading S{\`a}rl. Astrid Ledgaard Holm is an employee of Medtronic Denmark. Samuel Joseph Paul Malkin is an employee of Ossian Health Economics and Communications GmbH, which received consulting fees to support preparation of the cost-effectiveness manuscript. Editorial support for the response letter was provided by Covalence Research Ltd, which was funded by Medtronic International Trading S{\`a}rl. ",
year = "2022",
month = may,
doi = "10.1007/s13300-022-01252-w",
language = "אנגלית",
volume = "13",
pages = "1125--1129",
journal = "Diabetes Therapy",
issn = "1869-6953",
publisher = "Springer Publishing Company",
number = "5",
}
